Business
Puma Biotechnology to Present at the H.C. Wainwright 27th Annual Global Investment Conference
LOS ANGELES, September 02, 2025--On 9/8/25, Puma Biotechnology CEO and President Alan Auerbach will present a company overview at the H.C. Wainwright Global Investment Conference.
About this update from Puma Se
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2400,"height":800,"url":"https://media.zenfs.com/en/business-wire.com/6f8da40e441795563ba474eb5785236a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/A.p8L4mFcxyKqRdL0ef_Hg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMyMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/6f8da40e441795563ba474eb5785236a","width":960,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Wq1Gw3DHvTdt.DiKxSPiSA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/6f8da40e441795563ba474eb5785236a","width":1200,"height":400}},"lazy":false},{"type":"text","content":"LOS ANGELES, September 02, 2025--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 1:00 p.m. EDT on Monday, September 8, at the H.C. Wainwright 27th Annual Global Investment Conference. The conference will be held September 8–10, 2025 at the Lotte New York Palace Hotel in New York City.","length":466,"tagName":"p"},{"type":"text","content":"A live webcast of the presentation will be available on the Company’s website at https://www.pumabiotechnology.com. The presentation will be archived on the website and available for 30 days.","length":191,"tagName":"p"},{"type":"text","content":"About Puma Biotechnology","length":24,"tagName":"p"},{"type":"text","content":"Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral) in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or mo...